Typhoid Vi Polysaccharide Vaccine Market Outlook 2025–2034: Identifying Growth Drivers, Technology Trends, and Policy Impact
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Typhoid Vi Polysaccharide Vaccine Market Size From 2025 to 2034?
In recent times, there has been a significant expansion in the typhoid vi polysaccharide vaccine market. This market is expected to rise from $5.78 billion in 2024 to $6.71 billion in 2025, boasting a compound annual growth rate (CAGR) of 16.1%. Factors such as the prevalence of the disease, worldwide health campaigns, vaccination of travelers, government-driven immunization programs, as well as the effectiveness and safety of the vaccine, have been the driving forces behind the growth witnessed in the historic period.
In the coming years, the market for the Typhoid vi polysaccharide vaccine is projected to experience swift expansion. It is expected to reach a size of$13.09 billion by 2029,” growing at a Compound Annual Growth Rate (CAGR) of 18.2%. This anticipated growth over the prediction period can be linked to factors such as the broadening of immunization programs, focus on global health policies, epidemiological monitoring, an increase in demand in the field of travel medicine, as well as environmental and societal influences. The forecast period is also likely to witness major trends such as heightened investment in R&D, stronger regulatory support, key epidemiological research, and increased public health consciousness.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp
What Are the Core Market Drivers Propelling Growth in the Typhoid Vi Polysaccharide Vaccine Industry?
Anticipated growth in the typhoid VI polysaccharide vaccine market is largely driven by an increasing prevalence of typhoid. Typhoid, a potentially fatal infection, is engendered by the bacteria Salmonella typhi and is often transmitted through tainted food or beverages. The typhoid Vi polysaccharide vaccine serves as an immunizing agent for adults and children over the age of 2 against typhoid fever that is caused by Salmonella enterica serovar Typhi, or S. Typhi. The UK Health Security Agency, a governmental organization based in the UK, published data in August 2024 indicating a rise in laboratory-confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland from 2021 to 2022. The report highlighted an increase in S. Typhi from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. Hence, the mounting prevalence of typhoid is a key catalyst for the expansion of the typhoid Vi polysaccharide vaccine market.
How Is the Typhoid Vi Polysaccharide Vaccine Market Segmented?
The typhoid vi polysaccharide vaccinemarket covered in this report is segmented –
1) By Type: Child; Adult
2) By Route Of Administration: Oral; Parenteral
3) By Application: Government Institution; Private Sector; Other Applications
Subsegments:
1) By Child: Pediatric Formulations; Age-Specific Dosages
2) By Adult: Standard Adult Formulations; High-Risk Population Formulations
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=8313&type=smp
Which Regions Are Driving the Next Phase of the Typhoid Vi Polysaccharide Vaccine Market Growth?
Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Market Trends and Innovations Are Shaping the Future of the Typhoid Vi Polysaccharide Vaccine Industry?
The emergence of strategic alliances is a significant trend gaining ground in the typhoid Vi polysaccharide vaccine sector. Major players in this market are forging partnerships to consolidate their market position. For example, in July 2022, the International Vaccine Institute, an organization based in South Korea that focuses on globally significant infectious diseases like cholera, typhoid, shigella, and salmonella, collaborated with Moderna, an American biopharmaceutical corporation. This collaboration resulted in the creation of the world’s first economically viable oral cholera vaccine and a novel generation typhoid conjugate vaccine.
View the full report here:
How Is the Typhoid Vi Polysaccharide Vaccine Market Defined and What Are Its Core Parameters?
Typhoid VI polysaccharide vaccine refers to the recommendation of active immunization for people aged two and up, concerning the prevention of typhoid fever caused by Salmonella typhi.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8313
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
